No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA GroupTamara Castaño-Bonilla, Pau Montesinos, Alejandro Sanz et al.|Disease Markers|2022Cited by 2
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registryAna Alfonso Piérola, David Martínez‐Cuadrón, Rebeca Rodríguez‐Veiga et al.|Leukemia|2025Cited by 1